GlassScriptPhysician profile
Daniel Yugi Patten
NPI 1245490390
$1,853.50
in general payments reported to CMS, 2019-2025
23 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.83 · 2020: $158 · 2021: $283 · 2022: $355 · 2023: $330 · 2024: $355 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $912.12 | 2021-2025 | |
| Novo Nordisk INC | $215.06 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $118.33 | 2020-2025 | Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.14 | 2019-2025 | Xifaxan |
| Amgen INC. | $59.84 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $59.63 | 2024-2025 | Voquezna |
| Allergan, INC. | $48.79 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.47 | 2022 | |
| Corium, LLC | $30.19 | 2023-2025 | Azstarys |
| Genentech USA, INC. | $28.33 | 2020-2022 | |
| Pfizer INC. | $27.34 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $23.87 | 2024 | Gvoke Hypopen |
| Abbott Laboratories | $23.72 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.68 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.29 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $18.15 | 2023 | Veozah |
| Lundbeck LLC | $16.41 | 2025 | Rexulti |
| Medtronic, INC. | $15.85 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.16 | 2024 | Dupixent |
| Glaxosmithkline, LLC. | $12.90 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.65 | 2021 | |
| Innocoll Pharmaceuticals Limited | $12.56 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Patten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.